NASDAQ:IBRX

ImmunityBio (IBRX) Stock Price, News & Analysis

ImmunityBio logo
$6.02 -0.56 (-8.45%)
Closing price 03:58 PM Eastern
Extended Trading
$6.09 +0.08 (+1.25%)
As of 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About ImmunityBio Stock (NASDAQ:IBRX)

Advanced

Key Stats

Today's Range
$6.00
▼
$6.53
50-Day Range
$5.98
▼
$10.51
52-Week Range
$1.95
▼
$12.43
Volume
10.56 million shs
Average Volume
19.79 million shs
Market Capitalization
$6.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
Consensus Rating
Moderate Buy

Company Overview

ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body’s natural and adaptive immune responses.

The company’s lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. ImmunityBio also has investigational treatments in development for cancer and other diseases.

ImmunityBio was formed through the combination of ImmunityBio and NantKwest, completed in 2021. The company is based in California and conducts research and development and commercial activities focused on bringing its therapies to patients.

AI Generated. May Contain Errors.

ImmunityBio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

IBRX MarketRank™: 
1.72884378 of 5 stars

ImmunityBio scored higher than 35% of companies evaluated by MarketBeat, and ranked 642nd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ImmunityBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    ImmunityBio has a consensus price target of $16.00, representing about 166.0% upside from its current price of $6.02.

  • Amount of Analyst Coverage

    ImmunityBio has only been the subject of 4 research reports in the past 90 days.

  • Read more about ImmunityBio's stock forecast and price target.
  • Earnings Growth

    Earnings for ImmunityBio are expected to decrease in the coming year, from ($0.47) to ($0.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ImmunityBio is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ImmunityBio is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    35.09% of the float of ImmunityBio has been sold short.
  • Short Interest Ratio / Days to Cover

    ImmunityBio has a short interest ratio ("days to cover") of 10.77, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in ImmunityBio has recently increased by 2.55%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    ImmunityBio does not currently pay a dividend.

  • Dividend Growth

    ImmunityBio does not have a long track record of dividend growth.

  • News Sentiment

    ImmunityBio has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for ImmunityBio this week, compared to 9 articles on an average week.
  • Search Interest

    Only 34 people have searched for IBRX on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.
  • MarketBeat Follows

    Only 16 people have added ImmunityBio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ImmunityBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,119,838.00 in company stock.

  • Percentage Held by Insiders

    66.10% of the stock of ImmunityBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    8.58% of the stock of ImmunityBio is held by institutions.

  • Read more about ImmunityBio's insider trading history.
Receive IBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IBRX Stock News Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
See More Headlines

IBRX Stock Analysis - Frequently Asked Questions

ImmunityBio's stock was trading at $1.98 at the start of the year. Since then, IBRX stock has increased by 203.8% and is now trading at $6.0150.

ImmunityBio, Inc. (NASDAQ:IBRX) issued its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.14. The company had revenue of $51.24 million for the quarter, compared to analysts' expectations of $49.70 million.

ImmunityBio (IBRX) raised $205 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 9,531,200 shares at a price of $20.00-$23.00 per share.

ImmunityBio's top institutional shareholders include State Street Corp (1.99%), Goldman Sachs Group Inc. (0.39%), Cetera Investment Advisers (0.11%) and First Trust Advisors LP (0.11%). Insiders that own company stock include Barry J Simon, Cheryl Cohen and Christobel Selecky.
View institutional ownership trends
.

Shares of IBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunityBio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Palantir Technologies (PLTR), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA) and Super Micro Computer (SMCI).

Company Calendar

Last Earnings
8/04/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IBRX
CIK
1326110
Fax
N/A
Employees
691
Year Founded
2014

Price Target and Rating

High Price Target
$23.00
Low Price Target
$12.00
Potential Upside/Downside
+166.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.08)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$351.40 million
Net Margins
-607.79%
Pretax Margin
-607.89%
Return on Equity
N/A
Return on Assets
-54.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.27
Quick Ratio
4.27

Sales & Book Value

Annual Sales
$113.29 million
Price / Sales
56.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.08) per share
Price / Book
-5.57

Miscellaneous

Outstanding Shares
1,063,830,000
Free Float
360,637,000
Market Cap
$6.40 billion
Optionable
Optionable
Beta
0.17

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:IBRX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners